| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Sacubitril/valsartan |
| Brand | Entresto® |
| Indication | For the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients. |
| Assessment Process | |
| Rapid review commissioned | 06/11/2015 |
| Rapid review completed | 30/11/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 07/03/2016 |
| NCPE assessment completed | 08/07/2016 |
| NCPE assessment outcome | Reimbursement Recommended |
The NCPE considers valsartan/sacubitril (Entresto) cost-effective for the current licensed indication and recommends reimbursement.
The HSE has approved reimbursement following confidential price negotiations October 2017.
